Perfluorocarbon liquid (PFCL) has been widely used in vitreoretinal surgeries, especially in retinal detachment treatment. A prominent complication of intraoperative PFCL application is inadvertent subretinal PFCL retention. Subfoveal PFCL, even in small amounts, receives much attention due to its potential side effect on the macular structure and function. Whether to observe with follow-up or to deal with surgery is often an intractable problem in the management of subfoveal PFCL. Safety and necessity are the 2 key issues in considering surgical treatment, that is, can we avoid surgically induced macular injury and will surgery be beneficial for the recovery of vision? Herein, the authors review sub-foveal PFCL retention with its risk factors, morphological manifestations, pathological studies, clinical natural consequences, and different surgical methods with their outcomes. Analysis of the existing literature shows that visual acuity improved significantly after subfoveal PFCL removal or displacement and was positively correlated with visual acuity before the operation.

Keywords:
Subfoveal perfluorocarbon liquid, Vitreoretinal surgery, Complication, Retinal detachment
1.
Chang S, Ozmert E, Zimmerman NJ: Intraoperative perfluorocarbon liquids in the management of proliferative vitreoretinopathy. Am J Ophthalmol 1988; 106: 668–674.
2.
Chang S, Lincoff H, Zimmerman NJ, Fuchs W: Giant retinal tears. Surgical techniques and results using perfluorocarbon liquids. Arch Ophthalmol 1989; 107: 761–766.
3.
Dalma-Weiszhausz J, Franco-Cardenas V, Dalma A: Subretinal perfluorocarbon liquid for dissection of proliferative vitreoretinopathy. J Ophthalmic Vis Res 2012; 7: 350–354.
4.
Scott IU, Murray TG, Flynn HW Jr, Smiddy WE, Feuer WJ, Schiffman JC: Outcomes and complications associated with perfluoro-n-octane and perfluoroperhydrophenanthrene in complex retinal detachment repair. Ophthalmology 2000; 107: 860–865.
5.
Loewenstein A, Humayun MS, de Juan E Jr, Campochiaro PA, Haller JA: Perfluoroper-hydrophenanthrene versus perfluoro-n-octane in vitreoretinal surgery. Ophthalmology 2000; 107: 1078–1082.
6.
Bourke RD, Simpson RN, Cooling RJ, Sparrow JR: The stability of perfluoro-N-octane during vitreoretinal procedures. Arch Ophthalmol 1996; 114: 537–544.
7.
Shulman M, Sepah YJ, Chang S, Abrams GW, Do DV, Nguyen QD: Management of retained subretinal perfluorocarbon liquid. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 577–583.
8.
Garcia-Valenzuela E, Ito Y, Abrams GW: Risk factors for retention of subretinal perfluorocarbon liquid in vitreoretinal surgery. Retina 2004; 24: 746–752.
9.
Joondeph BC, Nguyen H: Ocular coherence tomography findings with retained submacular perfluoron. Clin Experiment Ophthalmol 2006; 34: 85–86.
10.
Yamakiri K, Uchino E, Sakamoto T: Soft shell technique during vitrectomy for proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 2016; 254: 1069–1073.
11.
Chan YK, Lu Y, Czanner G, Wu J, Cheng HC, Hussain R, Sakamoto T, Shum HC, Wong D: In vitro experiment to elucidate the mechanism of the “soft shell technique” for preventing subretinal migration of perfluoro-octane. Br J Ophthalmol 2017; 101: 389–394.
12.
Garg SJ, Theventhiran AB: Retained subretinal perfluorocarbon liquid in microincision 23-gauge versus traditional 20-gauge vitrectomy for retinal detachment repair. Retina 2012; 32: 2127–2132.
13.
Soheilian M, Nourinia R, Shoeibi N, Peyman GA: Three-dimensional OCT features of perfluorocarbon liquid trapped under the fovea. Ophthalmic Surg Lasers Imaging 2010, Epub ahead of print.
14.
Suk KK, Flynn HW Jr: Management options for submacular perfluorocarbon liquid. Ophthalmic Surg Lasers Imaging 2011; 42: 284–291.
15.
Sridhar J, Shahlaee A, Vander JF: En face optical coherence tomography of subfoveal perfluorocarbon liquid. Ophthalmology 2015; 122: 1853.
16.
Lesnoni G, Rossi T, Gelso A: Subfoveal liquid perfluorocarbon. Retina 2004; 24: 172–176.
17.
Tewari A, Eliott D, Singh CN, Garcia-Valenzuela E, Ito Y, Abrams GW: Changes in retinal sensitivity from retained subretinal perfluorocarbon liquid. Retina 2009; 29: 248–250.
18.
Nowilaty SR: Ten-year follow-up of retained subfoveal perfluoro-N-octane liquid. Retin Cases Brief Rep 2007; 1: 41–43.
19.
Cohen SY, Dubois L, Elmaleh C: Retinal hole as a complication of long-standing subretinal perfluorocarbon liquid. Retina 2006; 26: 843–834.
20.
Le Tien V, Pierre-Kahn V, Azan F, Renard G, Chauvaud D: Displacement of retained subfoveal perfluorocarbon liquid after vitreoretinal surgery. Arch Ophthalmol 2008; 126: 98–101.
21.
Oellers P, Charkoudian LD, Hahn P: Spontaneous resolution of subfoveal perfluorocarbon. Clin Ophthalmol 2015; 9: 517–519.
22.
Kim JM, Woo SJ, Park KH, Chung H: Surgical removal of retained subfoveal perfluorocarbon liquid through a therapeutic macular hole with intravitreal PFCL injection and gas tamponade. Korean J Ophthalmol 2013; 27: 392–395.
23.
de Queiroz JM Jr, Blanks JC, Ozler SA, Alfaro DV, Liggett PE: Subretinal perfluorocarbon liquids. An experimental study. Retina 1992; 12:S33–S39.
24.
Berglin L, Ren J, Algvere PV: Retinal detachment and degeneration in response to subretinal perfluorodecalin in rabbit eyes. Graefes Arch Clin Exp Ophthalmol 1993; 231: 233–237.
25.
Lee GA, Finnegan SJ, Bourke RD: Subretinal perfluorodecalin toxicity. Aust NZ J Ophthalmol 1998; 26: 57–60.
26.
Saatci AO, Koçak N: Retained submacular perfluorodecalin. Can J Ophthalmol 2003; 38: 293–296.
27.
Yiu G, Fekrat S, Hahn P: Spontaneous peripheral migration of subfoveal perfluorocarbon. Retina 2014; 34: 2315–2316.
28.
Escalada Gutierrez F, Mateo Garcia C: Extraction of subfoveal liquid perfluorocarbon. Arch Soc Esp Oftalmol 2002; 77: 519–521.
29.
Lai JC, Postel EA, McCuen BW 2nd: Recovery of visual function after removal of chronic subfoveal perfluorocarbon liquid. Retina 2003; 23: 868–870.
30.
Roth DB, Sears JE, Lewis H: Removal of retained subfoveal perfluoro-n-octane liquid. Am J Ophthalmol 2004; 138: 287–289.
31.
García-Arumí J, Castillo P, López M, Boixadera A, Martínez-Castillo V, Pimentel L: Removal of retained subretinal perfluorocarbon liquid. Br J Ophthalmol 2008; 92: 1693–1694.
32.
Vilaplana D, Poposki V, Martinez-Palmer A, Castilla M: Subfoveal perfluorocarbon liquid. Two new cases. Arch Soc Esp Oftalmol 2009; 84: 363–366.
33.
Joondeph BC: Controlled aspiration of subfoveal perfluorocarbon liquid using a novel microcannula. Retina 2011; 31: 991–993.
34.
Pfriem M, Hoerauf H: Removal of centrally located subretinal perfluorocarbon liquid. Klin Monbl Augenheilkd 2012; 229: 728–731.
35.
Ting DS, Lu VH, Tan GS, Wong EY: A surprising visual improvement following a prolonged 5-month retained subfoveal perfluorocarbon liquid. Int J Ophthalmol 2016; 9: 1079–1081.
36.
De Cilla S, Alkabes M, Radice P, Carini E, Mateo C: Direct transretinal removal of subfoveal perfluorocarbon liquid: the role and timing of internal limiting membrane peeling. Eur J Ophthalmol 2017; 27: 249–252.
37.
Lemley CA, Kim JE: Subretinal perfluorocarbon removal: perfluorocarbon volume estimation and cannula choice. Retina 2008; 28: 167–170.
38.
Sakurai E, Ogura Y: Removal of residual subfoveal perfluoro-n-octane liquid. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1063–1064.
39.
Sierra-Rodriguez MA, Lopez-Lopez JM, Jimenez-Prada de Miguel S: Subfoveal per-fluorocarbon liquid. Removal after three months. Arch Soc Esp Oftalmol 2016; 91: 596–598.
40.
Smith AG, Cost BM, Ehlers JP: Intraoperative OCT-assisted subretinal perfluorocarbon liquid removal in the DISCOVER Study. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 964–966.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.